LEADER 05145nam 2200601 450 001 9910460215803321 005 20191016113736.0 010 $a1-908230-51-7 035 $a(CKB)3710000000244628 035 $a(EBL)1887932 035 $a(SSID)ssj0001397297 035 $a(PQKBManifestationID)11771210 035 $a(PQKBTitleCode)TC0001397297 035 $a(PQKBWorkID)11414687 035 $a(PQKB)10733983 035 $a(MiAaPQ)EBC1887932 035 $a(MiAaPQ)EBC5897857 035 $a(Au-PeEL)EBL5897857 035 $a(OCoLC)893683608 035 $a(EXLCZ)993710000000244628 100 $a20191016d2015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAcanthamoeba $ebiology and pathogenesis /$fedited by Naveed Ahmed Khan, Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan 205 $aSecond edition. 210 1$aNorfolk, England :$cCaister Academic Press,$d[2015] 210 4$dİ2015 215 $a1 online resource (346 p.) 300 $aDescription based upon print version of record. 311 $a1-908230-50-9 320 $aIncludes bibliographical references (pages 285-328) and index. 327 $aContents; Current books of interest; Preface to the First Edition; Preface ; A: Biology and Phylogeny ; A.1 Introduction; A.2 Discovery of Acanthamoeba spp.; A.3 Speciation and genotyping; A.4 Cell biology ; A.5 Nuclear genome ; A.6 Mitochondrial genome ; A.7 The complete Acanthamoeba castellanii genome ; A.8 Motility ; A.9 Molecular basis of motility ; A.10 Acanthamoeba actin; A.11 Acanthamoeba myosin ; B: Life Cycle and Ecological Significance; B.1 Ecology; B.2 Ecosystem; B.3 Life cycle ; B.4 Stress management in cyst-forming pathogenic free-living protists 327 $aB.5 Regulators of the life cycle B.6 What stimulates encystation? ; B.7 Feeding; B.8 Metabolism; B.9 Acanthamoeba is a heterotroph (chemo-organotroph); B.10 Hydrogenosomal-type anaerobic ATP generation pathway in Acanthamoeba castellanii; B.11 Isolation of Acanthamoeba from the environmental samples; B.12 Storage ; B.13 Testing viability of trophozoites and cysts; C: Acanthamoeba Infections ; C.1 Acanthamoeba keratitis; C.2 Granulomatous amoebic encephalitis due to Acanthamoeba; C.3 Cutaneous acanthamoebiasis; C.4 Multiple sclerosis and Acanthamoeba; D: Pathogenesis 327 $aD.1 Acanthamoeba keratitis D.2 Granulomatous amoebic encephalitis due to Acanthamoeba; D.3 Loss and gain of virulence; D.4 Acanthamoeba: an opportunistic pathogen; D.5 Crossing of the biological barriers ; D.6 Direct virulence factors ; D.7 Contact-dependent mechanisms ; D.8 Contact-independent mechanisms ; D.9 Indirect virulence factors; E: Acanthamoeba and the Immune System; E.1 Non-specific immune system ; E.2 Specific immune system ; E.3 What are the basic types of parasite immune evasion strategies?; E.4 Acanthamoeba and immune response 327 $aE.5 Effect of immune suppressive component in marijuana, cannabinoid delta-9-tetrahydrocannabinol on Acanthamoeba encephalitis E.6 Acanthamoeba and the central nervous system autoimmunity; F: Chemotherapeutic Strategies Against Acanthamoeba Infections ; F.1 Chemotherapeutic agents and Acanthamoeba; F.2 Membrane-acting agents ; F.3 Inhibitors of DNA synthesis and polyamine metabolism ; F.4 RNA synthesis inhibition ; F.5 Protein synthesis inhibition ; F.6 Tricyclic neuroleptic agents (calmodulin inhibition); F.7 Artesunate 327 $aF.8 Antimicrobial compounds from natural products (in addition to the aforementioned antibiotics) F.9 Drug targets in Acanthamoeba; F.10 Drug resistance in Acanthamoeba; F.11 Disinfectants and Acanthamoeba; F.12 Future prospects for treatment ; G: War of the Microbial Worlds: Who is the Beneficiary in Acanthamoeba Interactions with Other Microbes; G.1 A host for viruses; G.2 A host for yeast; G.3 A host for protists; G.4 Acanthamoeba and bacteria interactions ; G.5 Is Acanthamoeba an evolutionary ancestor of macrophages?; G.6 Acanthamoeba as evolutionary precursor of pathogenicity 327 $aG.7 Who is the beneficiary in bacteria-Acanthamoeba interactions? 330 $aThis fully up-to-date book covers all aspects of Acanthamoeba biology. Following the success of the first edition, the author has extensively revised and expanded the text to produce a new volume that includes all the latest research and information on every aspect of this organism. There is a particular emphasis on the Acanthamoeba genome sequence and the novel insights gained from the application of molecular methods to Acanthamoeba developmental/cellular biology, in terms of metabolism and morphogenesis, classification, ecology and role in the ecosystem, host-pathogen interactions, virulenc 606 $aAcanthamoeba 608 $aElectronic books. 615 0$aAcanthamoeba. 676 $a593 702 $aKhan$b Naveed Ahmed 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910460215803321 996 $aAcanthamoeba$92202809 997 $aUNINA LEADER 01246nam 2200373Ia 450 001 9910699375703321 005 20230902162154.0 035 $a(CKB)5470000002402157 035 $a(OCoLC)500872325 035 $a(EXLCZ)995470000002402157 100 $a20100119d2000 ua 0 101 0 $aeng 135 $auran||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aGuidance for industry$b[electronic resource] $ereferencing discontinued labeling for listed drugs in abbreviated new drug applications 210 1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2000] 215 $a1 online resource (7 pages) 300 $a"Draft guidance." 300 $a"OGD." 300 $a"October 2000." 517 $aGuidance for industry 606 $aDrug approval$zUnited States 606 $aDrugs$xLabeling$zUnited States 615 0$aDrug approval 615 0$aDrugs$xLabeling 712 02$aCenter for Drug Evaluation and Research (U.S.) 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910699375703321 996 $aGuidance for industry$93434577 997 $aUNINA